<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02332473</url>
  </required_header>
  <id_info>
    <org_study_id>TB1405IFN</org_study_id>
    <nct_id>NCT02332473</nct_id>
  </id_info>
  <brief_title>A Prospective Study of Combination of Peginterferon Alfa-2b (40kD, Y-shape) and GM-CSF in Chronic Hepatitis B</brief_title>
  <official_title>A Prospective Phase 2 Clinical Trial to Assess the Efficacy and Safety of Combination of Peginterferon Alfa-2b (40kD, Y-shape) and GM-CSF in Chronic Hepatitis Patients.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Xiamen Amoytop Biotech Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Peking University First Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Xiamen Amoytop Biotech Co., Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a multi-center, randomized, prospective open-label study to assess the efficacy
      and safety of combination of peginterferon alfa-2b (40kD, Y-shape) and GM-CSF in
      interferon-naïve chronic hepatitis B patients with HBeAg positive. Patients were randomized
      to one of the 2 groups to receive different antiviral treatment.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2014</start_date>
  <completion_date type="Actual">August 2016</completion_date>
  <primary_completion_date type="Actual">February 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of HBeAg seroconversion at the end of treatment</measure>
    <time_frame>week 48</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of HBsAg undetectable and seroconversion at the end of treatment</measure>
    <time_frame>week 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of HBeAg undetectable and seroconversion at week 12, 24, 36 and 48</measure>
    <time_frame>week 12, 24, 36 and 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of HBsAg and HBeAg from baseline at week 12, 24, 36, and 48</measure>
    <time_frame>week 12, 24, 36, and 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of HBV DNA from baseline and percentage of HBV DNA undetectable at week 12, 24, 36, and 48</measure>
    <time_frame>treatment week 12, 24, 36, and 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of ALT normalization at week 24, 36 and 48</measure>
    <time_frame>week 24 ,36 and 48</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">110</enrollment>
  <condition>Chronic Hepatitis B</condition>
  <arm_group>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Ypeginterferon alfa-2b,sc. Qw. 48 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ypeginterferon alfa-2b,sc. Qw. 48 weeks. Granulocyte-macrophage colony stimulating factor,sc.qd, the first three day of every 28 days, starting from interferon treatment week 13.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ypeginterferon alfa-2b</intervention_name>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_label>Arm B</arm_group_label>
    <other_name>peginterferon alfa-2b</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Granulocyte-macrophage colony stimulating factor</intervention_name>
    <arm_group_label>Arm B</arm_group_label>
    <other_name>GM-CSF</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18yrs≤age≤65yrs.

          -  17≤BMI(body mass index)≤28.

          -  HBsAg positive≥6 months.

          -  Serum HBV DNA≥20,000IU/ml, HBsAg positive and HBeAg positive at screening.

          -  2ULN≤ALT≤10ULN(ULN=upper limit of normal) at screening.

          -  Pregnancy test must be negative for female patients of childbearing potential. All
             patients take effective birth control measures during treatment and 6 months after the
             treatment.

          -  Agree to participate in the study and sign the informed consent.

        Exclusion Criteria:

          -  Pregnant or lactating females

          -  Interferon treatment history, or using nucleos(t)ide analogues for chronic hepatitis B
             treatment within the previous 6 months, or any evidence of nucleosi(t)ide analogues
             resistance .

          -  Receiving strong immunomodulatory agents (e.g., steroids, thymosin) for more than two
             weeks 6 months prior to screening.

          -  Receiving hepatotoxicity agents (e.g., aczone, erythromycin, fluconazole,
             ketoconazole, rifampicin) for more than two weeks 6 months prior to screening.

          -  Co-infected with active hepatitis A, hepatitis C, hepatitis D, and/or human
             immunodeficiency virus (HIV).

          -  History or evidence of a medical condition associated with chronic liver disease other
             than viral hepatitis (e.g., autoimmune hepatitis, alcoholic liver disease, toxin
             exposures.

          -  Suffering from any other acute or chronic infectious disease.

          -  Mental disorder or physical disability, or family history of neurological and
             psychiatric disorders.

          -  Neutrophil count &lt;1500 cells/mm3, or platelet count &lt;90000 cells/mm3 at screening.

          -  Child-Pugh≥B, or other evidence of liver decompensation (e.g. serum albumin&lt;35g/L ,
             prothrombin time&gt;3 seconds prolonged, serum bilirubin&gt;2ULN, prothrombin activity &lt;60%,
             history of liver decompensation).

          -  Serum creatinine level &gt;ULN in screening period.

          -  Serum creatine kinase level &gt;2ULN except for physiological factors (e.g., exercise).

          -  AFP&gt;100ng/L. If 50ng/L&lt;AFP&lt;100ng/L at screening, retest 2 weeks later, and if AFP
             &lt;50ng/L can enrolled, vs, excluded.

          -  Hepatocarcinoma or suffering from any other malignant tumor.

          -  Autoimmune disease(e.g., psoriasis, systemic lupus erythematosus).

          -  Moderate or severe hypertension, or mild hypertension without well controlled.

          -  With not well- controlled endocrine disease (e.g., thyroid dysfunction, diabetes
             mellitus).

          -  Drug abusing, or alcoholism.

          -  HBeAb positive or HBsAb positive at screening.

          -  Allergic to interferon, or GM-CSF, or any fragment of the study drug.

          -  Other conditions which in the opinion of the investigator precluding enrollment into
             the study(e.g., low compliance).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Peking University First Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Peking University People's Hosopital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fuzhou Infectious Disease Hospital</name>
      <address>
        <city>Fuzhou</city>
        <state>Fujian</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Xiamen Hospital of T.C.M</name>
      <address>
        <city>Xiamen</city>
        <state>Fujian</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nanfang Hospital</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Henan Provincial People's Hospital</name>
      <address>
        <city>Zhengzhou</city>
        <state>Henan</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tongji Hospital, Huazhong University of Science &amp; Technology</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Xiangya Second Hospital, Central-south University</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shenyang Sixed People's Hospital</name>
      <address>
        <city>Shenyang</city>
        <state>Liaoning</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ruijing Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Xijing Hospital</name>
      <address>
        <city>Xi'an</city>
        <state>Shanxi</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>First Affiliated Hospital of Wenzhou Medical College</name>
      <address>
        <city>Wenzhou</city>
        <state>Zhejiang</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 4, 2015</study_first_submitted>
  <study_first_submitted_qc>January 4, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 6, 2015</study_first_posted>
  <last_update_submitted>January 23, 2017</last_update_submitted>
  <last_update_submitted_qc>January 23, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 25, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Hepatitis B, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Peginterferon alfa-2b</mesh_term>
    <mesh_term>Interferon-alpha</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

